AI in Medical Devices Market Size & Share, by Component (Software, Hardware & Devices, Services); Device Type; Application; Technology; End user; Functionality; Deployment Mode - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

AI in Medical Devices Market - Regional Analysis

North America Market Insights

The North America AI in medical devices market is anticipated to garner the largest share of 40.6% by the end of the forecast period. The region’s dominance is highly propelled by strong regulatory support, early adoption of AI-enabled diagnostics, and advanced healthcare infrastructure. The region leads through continued innovations, a strong ecosystem of established medical technology giants and agile startups, which are focused on diagnostic accuracy and operational efficiency. In June 2025, IQVIA introduced new AI agents for life sciences and healthcare, which were developed in collaboration with NVIDIA to enhance workflows and accelerate insights. These agents leverage NVIDIA’s NIM Agent Blueprints, NeMo Customizer, and NeMo Guardrails to support tasks such as target identification, clinical data review, literature analysis, and HCP engagement, thus denoting a positive artificial intelligence (AI) in medical devices market outlook.

A sophisticated medical ecosystem and a large aging population that requires advanced diagnostic and monitoring tools are the main factors that are responsible for uplifting artificial intelligence in medical devices market in the U.S. The landscape is moving toward integrated ecosystems where software defines hardware, shifting traditional sales models into recurring value subscriptions that combine devices with paid analytics. In this context, the Congress Government in December 2024 reported that the adoption of AI in health care has remarkably accelerated, positively impacted by the increased availability of clinical data and advancements in machine learning, deep learning, and neural networks, enabling a very accurate analysis of medical records, imaging, and patient histories. It also mentioned that federal oversight has evolved along with these technologies, wherein the agencies are establishing standards for algorithm transparency and interoperability, hence suitable for standard market growth.

A strong emphasis on digital health integration within a publicly funded healthcare system is responsibly boosting the overall AI in medical devices market in Canada. The landscape is effectively reshaped by Health Canada’s modernization of regulatory frameworks, which allow for iterative algorithm updates without repeated license amendments. In April 2026, the IRPP Organization revealed that AI scribes are utilized in the country’s healthcare to reduce physicians’ documentation time by up to 90%, but they raise serious concerns around privacy, accuracy, and equity. Besides the trials of tools such as DAX Copilot show promise in efficiency, yet risks such as transcription errors, bias, and patient data misuse are unresolved. Therefore, there is an urgent need for stronger governance, explicit consent, and safeguards to ensure these technologies enhance care without any compromise on patient trust or safety.

APAC Market Insights

The Asia Pacific artificial intelligence in medical devices market is expected to grow at the quickest rate from 2026 to 2035. The region’s progress in this field is largely propelled by rapid healthcare infrastructure modernization and a massive, aging patient population. The landscape is transitioning from experimental pilots to integrated clinical ecosystems wherein the multimodal AI combines imaging, genomics, and real-time data from AI-powered wearables to enable predictive, preventive care. In February 2026, an NIH article revealed that a study in Japan analyzed healthcare providers’ perspectives on AI, whereas the focus group interviews with 37 doctors, nurses, and allied professionals examined applications in lung cancer detection, clinical note generation, and wearable monitoring devices. In this context, participants acknowledged AI’s complete potential to support clinical decision-making and reduce workload, but there were concerns about algorithmic accuracy, bias, over-reliance, and shifts in professional roles. In addition, the study highlights that human-centered design and adaptive governance are highly essential for an effective integration of AI in healthcare systems.

The China AI in medical devices market is solidifying its position in the region based on a unique combination of centralized health data, state-led strategic support, and an opportunistic domestic ecosystem.  The sector is highly focused on lifecycle governance, cross-border data compliance, and the integration of AI into smart hospitals, with a main goal to bridge the specialist gap between urban centers and rural townships. In this context, NIH in March 2026 stated that its study on AI-based medical device approvals in China from 2020 to mid-2025 identified 154 devices, with annual approvals rising from 9 in 2020 to 45 in 2024, reflecting a 49.53% CAGR. It mentioned that most devices 79.9% were high-risk class III, which were using deep learning algorithms, and focused on radiology with CT-based applications for pulmonary and cardiovascular assessment. Clinical trials were the main evaluation pathway, particularly for class III devices, whereas the artificial intelligence (AI) in medical devices market was concentrated among a few manufacturers in major innovation hubs such as Beijing, Shanghai, Shenzhen, and Hangzhou.

Fueled by an urgent need to bridge healthcare accessibility gaps and the rising prevalence of chronic diseases, the artificial intelligence in medical devices market in India is expected to witness tremendous progress over the forecasted years. The sector is moving from a heavy reliance on imports toward becoming a global innovation hub, supported by government initiatives such as the Make in India campaign and production-linked incentive schemes that encourage local manufacturing. In March 2026, the Press Information Bureau (PIB) revealed that the country’s Ministry of Health and Family Welfare has launched the Secure AI in Health initiative and the Benchmarking Open Data Platform for Health AI, with a main goal to strengthen safe and evidence-based AI adoption in healthcare. SAHI provides national guidance for ethical and inclusive AI use, whereas BODH, developed with IIT Kanpur, enables structured testing and validation of AI tools before large-scale deployment. Furthermore, under the Medical Devices Rules, AI-enabled devices need to meet strict documentation, safety, and performance requirements for licensing as well as commercialization, thus denoting a positive artificial intelligence (AI) in medical devices market outlook.

Europe Market Insights

Europe AI in medical devices market is expected to witness noteworthy growth, which is facilitated by a strong emphasis on integrating high-tech solutions. The region has registered itself as a predominant leader in AI-driven diagnostics, particularly in oncology and cardiology, where machine learning algorithms enhance the precision of medical imaging and pathology. In this context, NIH in September 2024 revealed that the EU AI Act, which was approved in March 2024, formed a regulatory framework for AI systems, including AI and ML-enabled medical devices, classifying them as risky attributes and leading them to strict compliance requirements. This particular act applies extraterritorially to providers whose AI outputs are used in the region, thereby intersecting with existing regulations. In this context, providers need to implement an AI quality management system, maintain detailed technical documentation, and conduct post-market monitoring, with the option to integrate AI documentation into the medical device technical file, thus allowing safe and effective products to the market.

The Germany AI in medical devices market has registered itself as a powerhouse characterized by its integration within a mature, research-heavy industrial landscape and a robust public healthcare system. Technological advancements are particularly prominent in AI-enabled diagnostic imaging, robotic-assisted surgery, and the rapidly expanding field of DiGAs, i.e., reimbursable digital health applications. As of the November 2025 data from the Federal Ministry of Health, it emphasizes that advancing digitalisation is highly essential for modernising Germany’s healthcare system, improving care quality, and enabling patient-centred treatment. Besides, the key initiatives include the expansion of secure telematics infrastructure, implementation of electronic patient records, e-prescriptions, digital health applications, and telemedicine services. At the same time, legislative frameworks such as the Digital Act and Health Data Use Act deliberately support data-driven innovation and research, whereas the Health Data Lab and interoperability platforms strengthen the infrastructure for AI and digital medical solutions.

The government and health system bodies that are actively shaping both regulation and adoption of AI‑enabled medical technologies are reorganizing the growth dynamics of AI in medical devices market in the UK. The country’s regulatory landscape is evolving towards a light-touch approach by prioritizing ethical, secure, and robust AI solutions. Based on the government data published in February 2025, the MHRA’s Software Group looks into the regulation of software and AI as medical devices (SaMD and AIaMD) in the UK, ensuring safety, clinical effectiveness, and public access at the same time, guiding classification, qualification, and vigilance. Their change programme addresses pre- and post-market requirements, adaptive AI regulation, transparency, and international alignment with the FDA as well as Health Canada standards. Furthermore, the group also supports digital mental health technologies, collaborates with academic and healthcare partners, promotes good machine learning practices, and regulatory innovation, thus suitable for standard AI in medical devices market growth.